Yuko Waseda1,2,3, Masahide Yasui4, Kousuke Kurokawa5, Ryo Chikazawa5, Toshihiro Takeda5, Miho Mitsui5, Tomoaki Sonoda5, Makiko Yamaguchi5, Satoshi Watanabe6, Hazuki Takato7, Yukari Ichikawa8, Yukihiro Umeda5, Masaki Anzai5, Hiroshi Ueda9, Kazuo Kasahara6, Tamotsu Ishizuka5. 1. Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, 910-1193, Eiheiji, Fukui, Japan. yuwaseda@gmail.com. 2. Department of Respiratory Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. yuwaseda@gmail.com. 3. Department of Surgery, Houju Memorial Hospital, Nomi, Japan. yuwaseda@gmail.com. 4. Department of Respiratory Medicine, National Hospital Organisation Nanao National Hospital, Gifu, Japan. 5. Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, 910-1193, Eiheiji, Fukui, Japan. 6. Department of Respiratory Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. 7. Department of Respiratory Medicine, Japan Community Health Care Organisation Kanazawa Hospital, Kanazawa, Japan. 8. Department of Respiratory Medicine, Kanazawa Municipal Hospital, Kanazawa, Japan. 9. Department of Surgery, Houju Memorial Hospital, Nomi, Japan.
Abstract
BACKGROUND: Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biomarkers. METHODS: The study included 22 and 16 patients diagnosed with b- and d-pneumonia, respectively, at our institution or affiliated institutions. For d-pneumonia, the causative drug was minocycline hydrochloride in four patients, gefitinib in two patients, nivolumab in two patients, pembrolizumab in two patients, sulfasalazine in two patients, loxoprofen in one patient, Bouiougitou in one patient, edoxaban tosilate hydrate in one patient, and abemaciclib in one patient. White blood cell (WBC), C-reactive protein (CRP), Krebs von den Lungen-6 (KL-6), surfactant protein (SP)-D, and SP-A levels were measured in each patient and compared between the groups. RESULTS: Significant differences were noted in the WBC and SP-D levels between the two groups (P < 0.05, P < 0.001), but not in the CRP, KL-6, or SP-A levels. CONCLUSION: The study results suggest that SP-D is a useful marker for differentiating b-pneumonia and d-pneumonia.
BACKGROUND: Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biomarkers. METHODS: The study included 22 and 16 patients diagnosed with b- and d-pneumonia, respectively, at our institution or affiliated institutions. For d-pneumonia, the causative drug was minocycline hydrochloride in four patients, gefitinib in two patients, nivolumab in two patients, pembrolizumab in two patients, sulfasalazine in two patients, loxoprofen in one patient, Bouiougitou in one patient, edoxaban tosilate hydrate in one patient, and abemaciclib in one patient. White blood cell (WBC), C-reactive protein (CRP), Krebs von den Lungen-6 (KL-6), surfactant protein (SP)-D, and SP-A levels were measured in each patient and compared between the groups. RESULTS: Significant differences were noted in the WBC and SP-D levels between the two groups (P < 0.05, P < 0.001), but not in the CRP, KL-6, or SP-A levels. CONCLUSION: The study results suggest that SP-D is a useful marker for differentiating b-pneumonia and d-pneumonia.
Entities:
Keywords:
Bacterial pneumonia; Drug-induced pneumonia; Krebs von den Lungen-6; Surfactant protein A; Surfactant protein D